RespireRx Pharmaceuticals

    OverviewSuggest Edit

    RespireRx Pharmaceuticals Inc. (formerly Cortex Pharmaceuticals, Inc.) is focused on developing drug candidates to treat very large respiration related markets that are unserved or poorly served. RespireRx is also developing drugs for niche respiratory markets where premium pricing is probable. All of the Company’s current efforts are involved with sleep apnea/hypopnea, respiratory depression and respiratory distress.

    TypePublic
    Founded1988
    HQGlen Rock, US
    Websiterespirerx.com

    Latest Updates

    Employees (est.) (Dec 2018)2(-33%)
    Revenue (FY, 2012)$48.3 K

    RespireRx Pharmaceuticals Office Locations

    RespireRx Pharmaceuticals has an office in Glen Rock
    Glen Rock, US (HQ)
    126 Valley Rd
    Show all (1)

    RespireRx Pharmaceuticals Financials and Metrics

    RespireRx Pharmaceuticals Revenue

    RespireRx Pharmaceuticals's revenue was reported to be $48.31 k in FY, 2012
    USD

    Net income (FY, 2018)

    (2.6m)

    EBIT (FY, 2018)

    (2.2m)

    Cash (31-Dec-2018)

    33.3k
    Annual
    USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

    Revenue

    48.3k

    General and administrative expense

    1.9m

    R&D expense

    826.7k

    Operating expense total

    7.4m5.3m8.5m4.2m2.2m
    Quarterly
    USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Revenue

    74.5k

    General and administrative expense

    389.4k759.3k438.6k

    R&D expense

    191.9k83.9k64.1k80.4k171.8k145.4k

    Operating expense total

    1.7m843.2k64.1k80.4k171.8k670.7k584.0k2.4m2.3m1.5m593.1k506.2k586.8k
    Annual
    USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

    Cash

    152.2k53.2k92.0k84.9k33.3k

    Accounts Receivable

    116.0m

    Inventories

    4.6m

    Current Assets

    169.2k85.8k195.7k176.7k121.1k
    Quarterly
    USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Cash

    224.3k7.6k311.9k172.7k32.9k154.2k53.2k404.5k6.1k347.3k39.6k220.9k30.8k52.2k266.0874.0

    Current Assets

    234.9k105.7k365.2k239.7k86.1k318.6k154.9k448.0k82.6k528.7k157.0k378.6k163.3k161.5k149.8k132.4k

    Total Assets

    3.7m135.3k441.2k311.8k166.2k395.1k226.0k513.6k137.2k577.8k200.7k411.3k190.7k183.6k164.2k143.0k

    Accounts Payable

    1.3m1.7m1.9m1.5m1.6m
    Annual
    USDFY, 2012FY, 2015FY, 2016FY, 2017FY, 2018

    Net Income

    (7.6m)(6.0m)(9.2m)(4.3m)(2.6m)

    Depreciation and Amortization

    26.4k7.1k7.0k5.2k

    Accounts Payable

    871.9k490.4k1.2m476.4k703.7k

    Cash From Operating Activities

    (1.9m)(1.3m)(1.3m)(697.0k)(427.4k)
    Quarterly
    USDQ3, 2012Q1, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018

    Net Income

    (3.7m)(837.4k)(1.4m)62.4k(643.1k)(728.0k)(2.0m)(2.3m)(2.7m)(5.4m)(2.4m)(1.5m)(3.1m)(3.7m)(746.7k)(1.4m)

    Depreciation and Amortization

    20.1k1.9k3.6k1.7k3.5k3.3k4.9k

    Accounts Payable

    666.8k195.1k1.9m1.5m1.6m327.4k519.8k334.9k643.7k277.0k463.5k141.4k336.5k

    Cash From Operating Activities

    (1.8m)(144.6k)(200.4k)(322.7k)(343.3k)(867.9k)(456.4k)(495.8k)(140.0k)(184.0k)
    Show all financial metrics

    RespireRx Pharmaceuticals Operating Metrics

    FY, 2016

    Phase I Trials Products

    1

    Phase II Trials Products

    4

    Preclinical Phase Products

    1
    Show all operating metrics

    RespireRx Pharmaceuticals News and Updates

    RespireRx Pharmaceuticals Inc. and Impression Healthcare Limited Announce Agreement to Explore Commercialization of Dronabinol for the Treatment of Obstructive Sleep Apnea (OSA) in Australia, New Zealand and Southeast Asia

    Glen Rock, N.J., Feb. 19, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the treatment of sleep-related breathing disorders, is pleased to announce that it has entered into a non-bi…

    RespireRx Pharmaceuticals Inc. Appoints James Sapirstein as Executive Vice Chairman of the Board of Directors

    Glen Rock, N.J, Jan. 03, 2019 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a clinical stage pharmaceutical company, focused on the development of medicines that promote neuronal signaling in diseases and disorders of neuronal dysfunction, is plea…

    RespireRx Pharmaceuticals Inc. Secures Clinical and Commercial Supply of Dronabinol for Obstructive Sleep Apnea with the Signing of a Development and Supply Agreement with Noramco, Inc.

    Glen Rock, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- September 10, 2018 /Globe Newswire – RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), is pleased to announce that on September 4, 2018, it entered into a dronabinol Development and Supply Agreement (“Agreement”) with N…

    RespireRx Pharmaceuticals Frequently Asked Questions

    • When was RespireRx Pharmaceuticals founded?

      RespireRx Pharmaceuticals was founded in 1988.

    • How many employees does RespireRx Pharmaceuticals have?

      RespireRx Pharmaceuticals has 2 employees.

    • Who are RespireRx Pharmaceuticals competitors?

      Competitors of RespireRx Pharmaceuticals include Amphastar Pharmaceuticals, E-Therapeutics and Generex Biotechnology.

    • Where is RespireRx Pharmaceuticals headquarters?

      RespireRx Pharmaceuticals headquarters is located at 126 Valley Rd, Glen Rock.

    • Where are RespireRx Pharmaceuticals offices?

      RespireRx Pharmaceuticals has an office in Glen Rock.

    • How many offices does RespireRx Pharmaceuticals have?

      RespireRx Pharmaceuticals has 1 office.